SNTI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Senti Biosciences's net margin of -49.65%. Senti Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Senti Biosciences has a consensus price target of $10.00, signalling upside risk potential of 205.34%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Senti Biosciences, analysts believe NovaBay Pharmaceuticals is more attractive than Senti Biosciences.

Senti Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Senti Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Senti Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Senti Biosciences's net income of -$28.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Senti Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences is 10.00x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -- compared to Senti Biosciences's net margin of -54.2%. Senti Biosciences's return on equity of -- beat PTC Therapeutics's return on equity of --.

Senti Biosciences has a consensus price target of $10.00, signalling upside risk potential of 205.34%. On the other hand PTC Therapeutics has an analysts' consensus of $58.36 which suggests that it could grow by 32.81%. Given that Senti Biosciences has higher upside potential than PTC Therapeutics, analysts believe Senti Biosciences is more attractive than PTC Therapeutics.

Senti Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Senti Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Senti Biosciences quarterly revenues are --, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Senti Biosciences's net income of -$28.9M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Senti Biosciences's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences is 10.00x versus 3.73x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Senti Biosciences's net margin of -2357.27%. Senti Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.

Senti Biosciences has a consensus price target of $10.00, signalling upside risk potential of 205.34%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Senti Biosciences, analysts believe Palatin Technologies is more attractive than Senti Biosciences.

Senti Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Senti Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Senti Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Senti Biosciences's net income of -$28.9M is lower than Palatin Technologies's net income of -$7.8M. Notably, Senti Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences is 10.00x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Senti Biosciences's net margin of --. Senti Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.

Senti Biosciences has a consensus price target of $10.00, signalling upside risk potential of 205.34%. On the other hand Theriva Biologics has an analysts' consensus of -- which suggests that it could grow by 6141.38%. Given that Theriva Biologics has higher upside potential than Senti Biosciences, analysts believe Theriva Biologics is more attractive than Senti Biosciences.

Senti Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.367%.

Senti Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Senti Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Senti Biosciences's net income of -$28.9M is lower than Theriva Biologics's net income of -$7.7M. Notably, Senti Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences is 10.00x versus 1.59x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.